{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-002152","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2022-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.349036+00:00","generated_at":"2026-06-27T17:59:30.461706+00:00","sec_items":["2.01","9.01","3.02","5.01","5.02","5.03","5.06"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Revelation Biosciences (f/k/a Petra Acquisition) closes de-SPAC merger; new board appointed","bullets":["Business combination of Petra Acquisition and Revelation Biosciences closed Jan 10, 2022; company renamed Revelation Biosciences.","Holders of 3,480,362 Petra shares redeemed for ~$35.5M ($10.20/share); ~$7.6M escrowed, ~$4.2M released to company.","Immediately post-closing: 12,944,213 common shares outstanding; 10,490,461 warrants and 460,706 RSUs outstanding.","New board appointed: George Tidmarsh, James Rolke, Jennifer Carver, Jess Roper, Curt LaBelle; prior Petra directors/officers resigned.","Petra ceased to be a shell company; common stock begins trading on Nasdaq under REVB, REVBU, REVBW."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-002152","json":"https://secwatch.observer/filing/0001213900-22-002152.json","markdown":"https://secwatch.observer/filing/0001213900-22-002152.md","text":"https://secwatch.observer/filing/0001213900-22-002152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/0001213900-22-002152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/ea154019-8k_revelation.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T17:59:30.461706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17128cf004","claim":"Andreas Typaldos departed as Director at REVELATION BIOSCIENCES, INC..","evidence_excerpt":"each of Andreas Typaldos, David Dobkin, Anthony Hayes, Robert Nicholson, Barry Dennis and William Carson ceased serving as a director of Petra","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/0001213900-22-002152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"49a820b837","claim":"William Carson departed as Director at REVELATION BIOSCIENCES, INC..","evidence_excerpt":"each of Andreas Typaldos, David Dobkin, Anthony Hayes, Robert Nicholson, Barry Dennis and William Carson ceased serving as a director of Petra","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/0001213900-22-002152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5dbff53aee","claim":"Andreas Typaldos departed as Executive Officer at REVELATION BIOSCIENCES, INC..","evidence_excerpt":"Andreas Typaldos and Sean Fitzpatrick ceased serving as executive officers of Petra","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/0001213900-22-002152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"62c330e3bd","claim":"Anthony Hayes departed as Director at REVELATION BIOSCIENCES, INC..","evidence_excerpt":"each of Andreas Typaldos, David Dobkin, Anthony Hayes, Robert Nicholson, Barry Dennis and William Carson ceased serving as a director of Petra","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/0001213900-22-002152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7957c4912a","claim":"David Dobkin departed as Director at REVELATION BIOSCIENCES, INC..","evidence_excerpt":"each of Andreas Typaldos, David Dobkin, Anthony Hayes, Robert Nicholson, Barry Dennis and William Carson ceased serving as a director of Petra","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/0001213900-22-002152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c5ea55c9c9","claim":"Sean Fitzpatrick departed as Executive Officer at REVELATION BIOSCIENCES, INC..","evidence_excerpt":"Andreas Typaldos and Sean Fitzpatrick ceased serving as executive officers of Petra","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/0001213900-22-002152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"cd9dd81d5f","claim":"Barry Dennis departed as Director at REVELATION BIOSCIENCES, INC..","evidence_excerpt":"each of Andreas Typaldos, David Dobkin, Anthony Hayes, Robert Nicholson, Barry Dennis and William Carson ceased serving as a director of Petra","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/0001213900-22-002152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f17b4d5b28","claim":"Robert Nicholson departed as Director at REVELATION BIOSCIENCES, INC..","evidence_excerpt":"each of Andreas Typaldos, David Dobkin, Anthony Hayes, Robert Nicholson, Barry Dennis and William Carson ceased serving as a director of Petra","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/0001213900-22-002152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}